Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The annual number of new cases is about 748,300, the number of deaths is 695,900, and nearly half of the new cases and deaths occur in China.[@b1-ott-11-1293] In recent years, with the development of surgical techniques, the prognosis of patients with HCC has improved. However, the clinical manifestations of HCC are not obvious; thus, its early diagnosis is difficult. Moreover, there is still a lack of specific markers for the diagnosis of HCC, and when HCC is diagnosed, it is frequently in late stage. Consequently, the rate of overall survival of patients with HCC is still poor.[@b2-ott-11-1293],[@b3-ott-11-1293] As a result, the search for reliable biomarkers to diagnose HCC and predict the survival rate of HCC patients has become a hot research topic in recent years.[@b4-ott-11-1293] Heat shock proteins (HSPs) are a family of conserved proteins produced by cells in response to stressful conditions. They play key roles in various cellular processes, such as maintaining cell homeostasis, apoptosis, invasion, cell signal transduction, and cellular response, and are closely related to the development of tumors.[@b5-ott-11-1293] In recent years, studies have found that the abnormal expression of HSPs is closely associated with the incidence and development of HCC, and can be used as one of the diagnosis and prognosis indicators.[@b6-ott-11-1293]

HSP27 is an important member of the HSP family, which plays a key role in the occurrence and development of tumors.[@b7-ott-11-1293] HSP27 has been found to be overexpressed in various cancers, including esophageal cancer,[@b8-ott-11-1293] gastric cancer,[@b9-ott-11-1293] colon cancer,[@b10-ott-11-1293] prostate cancer,[@b11-ott-11-1293] breast cancer,[@b12-ott-11-1293] lung cancer,[@b13-ott-11-1293],[@b14-ott-11-1293] and HCC.[@b15-ott-11-1293],[@b16-ott-11-1293] In addition, some studies have shown that HSP27 expression was related to the clinicopathological features and prognosis of the tumors. However, the relationship between HSP27 expression and the clinicopathological features of HCC, as well as its prognostic value in patients with HCC remains controversial. King et al[@b17-ott-11-1293] determined that the expression of HSP27 was associated with tumor differentiation and poor prognosis, but they found no association with other clinicopathological features. Also, Harimoto et al[@b18-ott-11-1293] found that the expression of HSP27 was not correlated with vascular invasion, metastasis, tumor differentiation, and other clinical features, and in addition, HSP27 expression was not related to the overall survival and disease-free survival in hepatitis C virus-positive HCC patients. Moreover, Zhang et al[@b19-ott-11-1293] found that the expression of HSP27 predicted a poor overall survival and short disease-free survival time. Accordingly, we conducted a meta-analysis to determine the clinicopathological and prognostic value of HSP27 in patients with HCC.

Methods
=======

Identification and eligibility of relevant studies
--------------------------------------------------

The PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI, and Wan Fang databases were searched to identify studies that evaluate the clinicopathological characteristics and prognostic value of HSP27 expression in HCC patients using immunohistochemistry (IHC) analysis. The search ended on September 1, 2017. Search words were "heat shock protein 27", "HSP27" and "liver cancer", "hepatic carcinoma", "hepatocellular carcinoma", "cancer of the liver". The reference list of the included studies was also checked to find other qualified studies.

The studies should meet the following inclusion criteria: 1) patients in the study should be clearly diagnosed with HCC; 2) the study is published in Chinese or English, and the full text is available; 3) the expression of HSP27 was measured by IHC analysis; 4) the article should be a case--control study and assess the relationship between HSP27 expression and the HCC clinicopathological features or prognosis, and the study should include at least one primary outcome of interest; and 5) repeat publications were excluded.

Data extraction
---------------

Two reviewers (Chaojie Liang and Hua Ge) independently screened all the articles according to the inclusion criteria. The extracted data included the first author's name, year of publication, sample size, country/region, antibody company, antibody concentration and clinicopathological parameters (HSP27 expression, gender, hepatitis B virus surface antigen \[HbsAg\], α-fetoprotein \[AFP\], tumor size, metastasis, vascular invasion, tumor differentiation, and TNM stage) and hazard ratios (HRs) with 95% CI for overall survival and disease-free survival. Disagreements were resolved by re-extraction or third-party adjudication.

Quality assessment
------------------

The quality of each of the included studies was assessed using the Newcastle--Ottawa Scale (NOS) criteria, and studies with NOS score of \>6 were regarded as good quality, while \<6 were considered as poor quality.

Statistical analysis
--------------------

The STATA 14.2 software was used for statistical analyses. The association between HSP27 expression and the clinicopathological features (gender \[male vs female\], AFP \[positive: negative ratio\], HbsAg \[yes vs no\], tumor size \[\>5 cm vs ≤5 cm\], metastasis \[yes vs no\], vascular invasion \[yes vs no\], tumor differentiation level \[low vs high or moderate\], and TNM stage \[I/II vs III/IV\] was evaluated by pooled odds ratios \[ORs\] with 95% CIs), and the differential expression of HSP27 between cancer tissues and control tissues was also evaluated. The software Engauge Digitizer 10.0 was used to extract the survival data from Kaplan--Meier curves in the articles. When the 95% CI did not overlap 1, it was considered to be statistically significant. The heterogeneity between the studies was evaluated by the *I*^2^ test. The fixed effects model was chosen when there was no significant heterogeneity (*I*^2^\<50%, P-Het \<0.1). When the heterogeneity was signifi-cant, the random effects model was used. Potential causes of statistical heterogeneity were analyzed by subgroup analysis. Publication bias was examined by the Begg's funnel plot test and inverted funnel plots.

Results
=======

Characteristics of studies
--------------------------

A total of 598 relevant articles were identified by searching the PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI, and Wan Fang databases, as illustrated in [Figure 1](#f1-ott-11-1293){ref-type="fig"}, which shows the details of the selection process. Ultimately, 11 eligible articles were included in this meta-analysis.[@b15-ott-11-1293]--[@b25-ott-11-1293] As shown in [Table 1](#t1-ott-11-1293){ref-type="table"}, these studies were published from 2000 to 2017, and included a total of 876 HCC patients. The sample size ranged from 34 to 194 patients, with 6 of studies including \>60 patients and 5 including ≤60 patients. Eight of the studies evaluated patients from China, 2 from Japan, and 1 from Korea. All these studies scored ≥6 in methodological assessment, which implied that they were of high quality.

The meta-analysis about the relationship between HSP27 expression and clinicopathological features in patients with HCC
-----------------------------------------------------------------------------------------------------------------------

The correlation between HSP27 expression and the clinicopathological features of HCC was assessed in this meta-analysis, and the results are shown in [Table 2](#t2-ott-11-1293){ref-type="table"}. Five studies, including a total of 237 patients were used to evaluate the differential expression of HSP27 in HCC and normal tissues. The results revealed that the expression of HSP27 in HCC was significantly higher than that in normal tissue (OR=7, 95% CI =2.35--20.79, *P*=0.000; [Figure 2A](#f2-ott-11-1293){ref-type="fig"}). The ORs for AFP were reported in 3 studies that included 167 cases. The results of our evaluation of these data indicated that HSP27 expression was associated with AFP expression (OR=3.86, 95% CI =1.11--13.39, *P*=0.034; [Figure 2C](#f2-ott-11-1293){ref-type="fig"}). Nine studies including 642 patients showed a significant relationship between HSP27 expression and tumor differentiation (OR=3.81, 95% CI =1.79--8.08, *P*=0.000; [Figure 4B](#f4-ott-11-1293){ref-type="fig"}). However, the expression of HSP27 was not significantly associated with any of the following parameters: gender (OR=1.13, 95% CI =0.72--1.77, *P*=0.606; [Figure 2](#f2-ott-11-1293){ref-type="fig"}), HBsAg (OR=1.72, 95% CI =0.65--4.52, *P*=0.275; [Figure 3A](#f3-ott-11-1293){ref-type="fig"}), tumor size (OR=1.19, 95% CI =0.74--1.92, *P*=0.479; [Figure 3B](#f3-ott-11-1293){ref-type="fig"}), metastasis (OR=1.96, 95% CI =0.91--4.24, *P*=0.083; [Figure 3C](#f3-ott-11-1293){ref-type="fig"}), vascular invasion (OR=1.71, 95% CI =0.93--3.15, *P*=0.083; [Figure 4A](#f4-ott-11-1293){ref-type="fig"}), and TNM stage (OR=0.66, 95% CI =0.27--1.61, *P*=0.358; [Figure 4C](#f4-ott-11-1293){ref-type="fig"}).

The meta-analysis about the prognostic value of HSP27 in patients with HCC
--------------------------------------------------------------------------

The relationship between HSP27 expression and the prognosis of patients with HCC was also assessed in this meta-analysis. The HRs for the overall survival rate were examined in 4 studies (Harimoto et al had 2 sets of data), which included 203 and 162 HCC patients with and without HSP27 expression, respectively. Our evaluation of the data revealed that HSP27 expression was associated with poor overall survival (positive: negative: HR =1.13, 95% CI =1.39--2.53, *P*=0.000; [Figure 5A](#f5-ott-11-1293){ref-type="fig"}). Additionally, we examined the HRs for disease-free survival rate in 3 studies (Harimoto et al had 2 sets of data), which included 135 and 150 HCC patients with and without HSP27 expression, respectively. The meta-analysis showed that HSP27 expression was not associated with disease-free survival (positive: negative: HR =1.54, 95% CI =0.93--2.14, *P*=0.673; [Figure 5B](#f5-ott-11-1293){ref-type="fig"})

Publication bias and sensitivity analysis
-----------------------------------------

No publication bias was found for HSP27 expression (*P*=0.086), gender (*P*=0.133), AFP (*P*=0.296), tumor size (*P*=1), metastasis (*P*=0.133), HBsAg (*P*=0.452), tumor differentiation (*P*=0.118), TNM stage (*P*=0.806), overall survival rate (*P*=0.308), and disease-free survival rate (*P*=0.734) according to the Begg's test. However, publication bias existed for vascular invasion (*P*=0.035) and the sensitivity analysis was calculated to determine whether individual studies influenced the pooled OR. The result indicated that no study substantially influenced the pooled OR, which suggested that more studies needed to be included for further research.

Discussion
==========

HSPs are widely found in prokaryotic and eukaryotic cells. They comprise various groups of conserved proteins that have important physiological functions and play key roles in cell growth, differentiation, and gene transcription.[@b26-ott-11-1293] In recent years, studies have found that HSPs are involved in the development of tumors.[@b27-ott-11-1293] HSP27 is a member of the HSP family, which acts as an ATPase-independent chaperone. Several studies suggest that HSP27 is involved in the regulation of cell cycle, inhibition of cell apoptosis, remodeling of skeletal structures, regulation of translation initiation, DNA repair, RNA cleavage, and ubiquitin--proteasome pathway degradation of oxidized proteins.[@b28-ott-11-1293] Additionally, it has been reported that Hsp27 can promote the metastasis ability of tumors through a variety of different molecular mechanisms. For instance, the mitogen-activated protein kinase kinase 4-mediated enhancement of cell invasion is mainly dependent on the role of Hsp27 and MMP2.[@b29-ott-11-1293] Moreover, Hsp27 maintains the stem cell characteristics of breast cancer stem cells by upregulating cell epithelial--mesenchymal transition (EMT) and the nuclear factor-kappa-B signaling pathway.[@b30-ott-11-1293]

HSP27 also plays an extremely important role in epidermal growth factor-, hepatocyte growth factor-, and interleukin-6- mediated EMT progression in prostate cancer.[@b11-ott-11-1293] HSP27 has also been suggested to promote tumor metastasis through the regulation of the transforming growth factor beta signaling pathway by activating the expression of MMP2.[@b31-ott-11-1293] HSP27 can act as a chaperone and perform different cellular functions due to its specific interaction with different binding proteins. For example, HSP27 interacts with tumor protein, translationally-controlled 1 (TPT1, also known as TCTP) and stabilizes the structure of TPT1, which, in turn, reduces the expression and activity of p53.[@b32-ott-11-1293] HSP27 also plays a role in inhibiting apoptosis by interacting with cytochrome-c and caspase-3.[@b33-ott-11-1293],[@b34-ott-11-1293] HSP27 directly interacts with AKT to increase its stability, which, in turn, leads to increased level of phosphorylation of p21, both of which are essential survival factors in DNA-damaged cells induced by ultraviolet radiation.[@b35-ott-11-1293] HSP27 interacts with insulin-like growth factor 1 and stabilizes the structure of the Bad/14-3-3 complex, allowing Bad to stay in the cytoplasm and preventing its translocation to the nuclei, thus promoting cell survival.[@b36-ott-11-1293] A recent report also suggested that HSP27 can also downregulate the hippo tumor suppressor pathway.[@b37-ott-11-1293] In addition, some studies have also shown that HSP27 can directly interact with 14-3-3ζ to promote the progression of non-small cell lung cancer.[@b38-ott-11-1293] Indeed, inhibition of HSP27 by small interfering RNA (siRNA) or antisense oligonucleotide significantly was found to increase the therapeutic effect of radiotherapy, paclitaxel, HSP90 inhibitor, MET kinase inhibitor, and gemcitabine.[@b39-ott-11-1293]--[@b42-ott-11-1293] In summary, HSP27 could become one of the molecular target of drugs for the treatment of tumors.

Recently, multiple studies demonstrated that HSP27 was highly expressed in a variety of cancers, and its expression was associated with the clinicopathological features and prognosis of the patients with these cancers.[@b14-ott-11-1293],[@b43-ott-11-1293] However, since the role of HSP27 in HCC remains controversial, we conducted this meta-analysis to clarify the association between HSP27 expression and clinicopathological features and prognosis in patients with HCC. The results of this meta-analysis, which included 876 patients from 11 studies, indicated that HSP27 was overexpressed in HCC patients and HSP27 expression is significantly related to AFP level, and tumor differentiation in HCC patients. Moreover, we also found that the positive expression of HSP27 predicted a poor overall survival rate, suggesting that HSP27 may be a reliable prognostic biomarker in HCC patients.

In this study, 2 of the articles included, namely Guo et al[@b21-ott-11-1293] and Joo et al,[@b24-ott-11-1293] suggested that HSP27 expression was related to the HBsAg. Additionally, 2[@b15-ott-11-1293],[@b22-ott-11-1293] of 6, 2[@b22-ott-11-1293] of 7, and 1[@b20-ott-11-1293] of 5 studies indicated that overexpression of HSP27 correlated with metastasis, vascular invasion, and TNM stage. However, the pooled results showed no statistically significant relationship between HSP27 and these clinicopathological features. Also, although King et al[@b17-ott-11-1293] and Zhang et al[@b19-ott-11-1293] suggested that expression of HSP27 indicated a poor disease-free survival, the results of this meta-analysis showed no statistical significance.

Recently, studies demonstrated that phosphorylated HSP27 may also play an important role in cancers. It has been reported that p-HSP27 was associated with the tumor diameter and portal vein invasion in HCC.[@b16-ott-11-1293] Moreover, p-HSP27 was related to EMT, apoptosis resistance.[@b44-ott-11-1293],[@b45-ott-11-1293] However, p-HSP27 may play a different role from HSP27. Studies found that reduced p-HSP27 was associated with HCC stage,[@b46-ott-11-1293] so further research should be performed to explore the various function of HSP27.

Limitations
===========

This meta-analysis has some limitations, including the following: 1) There may be some articles with controversial results that have not been published, which may have led to publication bias. 2) With regard to the experimental method, we only chose studies that used IHC analysis in this study. When we carefully read the contents of the articles, we found that the antibody manufacturer and antibody concentration used in the experiments were not the same, and the cut-off values for HSP27 expression differed among the articles. These differences are likely to affect the final result and cause bias, thus more studies with similar antibody, concentration of antibody, and cut-off criteria are needed in order to verify the results of this meta-analysis. 3) Studies included in this meta-analysis only comprised patients of Asian race, including Chinese, South Korean, and Japanese. Accordingly, these results may only be suitable for Asian races, and thus more studies from other areas are needed. 4) Some articles did not provide specific HRs value, which we extracted by software and may cause bias. 5) The number of studies and sample size included in this meta-analysis are limited. Thus, larger samples and additional high-quality studies are needed to confirm the results of this meta-analysis.

Conclusion
==========

Despite the limitations in this meta-analysis, the results are significant. The pooled results indicated that HSP27 expression was related to the incidence of HCC, AFP level, and tumor differentiation. Additionally, HSP27 may be a biomarker of unfavorable prognosis of patients with HCC. However, more high-quality studies are needed to achieve a more convincing statistical analysis.

This study was financially supported by the Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support (ZYLX201612), Capital Foundation of Medical Development (shoufa2016-2-2053), Beijing Tongren Hospital Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support (trzdyxzy201705).

**Disclosure**

The authors report no conflicts of interest in this work.

![Flowchart of study selection process.](ott-11-1293Fig1){#f1-ott-11-1293}

![Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and clinicopathological features.\
**Notes:** (**A**) Expression; (**B**) gender; (**C**) AFP level. Weights are from random effects analysis.\
**Abbreviations:** AFP, α-fetoprotein; OR, odds ratio.](ott-11-1293Fig2){#f2-ott-11-1293}

![Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and clinicopathological features.\
**Notes:** (**A**) HBsAg; (**B**) tumor size; (**C**) metastasis. Weights are from random effects analysis.\
**Abbreviation:** OR, odds ratio.](ott-11-1293Fig3){#f3-ott-11-1293}

![Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and clinicopathological features.\
**Notes:** (**A**) Vascular invasion; (**B**) tumor differentiation; (**C**) TNM stage. Weights are from random effects analysis.\
**Abbreviation:** OR, odds ratio.](ott-11-1293Fig4){#f4-ott-11-1293}

![Forest plot and funnel plots of studies evaluating the relationship between HSP27 expression and prognosis of HCC patients.\
**Notes:** (**A**) Overall survival; (**B**) disease-free survival. Weights are from random effects analysis.\
**Abbreviations:** HCC, hepatocellular carcinoma; HR, hazard ratio.](ott-11-1293Fig5){#f5-ott-11-1293}

###### 

Characteristics of studies included in the meta-analysis

  Authors                            Year    Country   Kind    No. of patients   Antibody company               Antibody concentration   Expression cancer (+/−), control (+/−)   Age \>60 (+/−), \<60 (+/−)   AFP positive (+/−), negative (+/−)   HBsAg yes (+^/^−), no (+/−)   Tumor size \#5 cm (+/−), \>5 (+/−)   Metastasis, metastasis (+/−), Non-metastasis (+/−)   Vascular invasion yes (+^/^−), no (+/−)   Differentiation low (+/−), high, and moderate (+/−)   UICC stage I, II (+/−), III, IV (+/−)   Survival information   Quality score
  ---------------------------------- ------- --------- ------- ----------------- ------------------------------ ------------------------ ---------------------------------------- ---------------------------- ------------------------------------ ----------------------------- ------------------------------------ ---------------------------------------------------- ----------------------------------------- ----------------------------------------------------- --------------------------------------- ---------------------- ---------------
  Shen et al[@b20-ott-11-1293]       2013    China     HCC     32                Fujian Maixin Technology       NA                       18/14                                    10/12                        10/4                                 10/8                          6/8                                  NA                                                   NA                                        12/0                                                  6/12                                    NA                     6
                                     3/32    8/2       8/20    8/6               12/6                                                                                             6/14                         12/2                                                                                                                                                                                                                                                                                                                        
  Guo[@b21-ott-11-1293]              2012    China     HCC     68                Fujian Maixin Technology       1:200                    51/17                                    NA                           NA                                   44/9                          26/7                                 15/4                                                 NA                                        23/2                                                  NA                                      NA                     6
                                     42/26                     7/8               25/10                          29/20                                                             28/15                                                                                                                                                                                                                                                                                                                                                    
  Dai et al[@b22-ott-11-1293]        2009    China     HCC     45                NeoMarkers                     NA                       30/15                                    21/12                        NA                                   NA                            18/10                                22/4                                                 24/6                                      II/I                                                  NA                                      NA                     6
                                     0/35    9/3                                 12/5                           8/11                     6/9                                      19/14                                                                                                                                                                                                                                                                                                                                                    
  Liang et al[@b15-ott-11-1293]      2011    China     HCC     34                NA                             NA                       20/14                                    NA                           NA                                   NA                            6/5                                  15/4                                                 12/1                                      15/5                                                  NA                                      NA                     6
                                     10/24                                       14/9                           5/10                     9/13                                     5/9                                                                                                                                                                                                                                                                                                                                                      
  Daimei et al[@b16-ott-11-1293]     2016    Japan     HCC     194               Streegen                       1:400                    118/76                                   97/53                        NA                                   20/11                         NA                                   28/51                                                71/41                                     20/10                                                 42/34                                   NA                     8
                                     NA      21/23             98/65                                            40/74                    47/35                                    98/66                        76/42                                                                                                                                                                                                                                                                                                                       
  Mee et al[@b24-ott-11-1293]        2005    Korea     HCC     71                NeoMarkers                     1:50                     44/27                                    NA                           NA                                   40/13                         16/8                                 12/10                                                16/12                                     36/15                                                 12/9                                    NA                     8
                                     NA                        4/14              28/19                          32/17                    28/15                                    8/12                         32/18                                                                                                                                                                                                                                                                                                                       
  John et al[@b23-ott-11-1293]       2006    China     HCC     67                Santa cruz                     1:500                    51/16                                    43/14                        22/1                                 44/14                         NA                                   NA                                                   33/8                                      NA                                                    34/8                                    NA                     8
                                     NA      8/2       29/15   7/2                                                                       18/8                                                                  17/8                                                                                                                                                                                                                                                                                                                        
  King et al[@b17-ott-11-1293]       2000    China     HCC     58                Novocastra Laboratories, Ltd   1:100                    28/30                                    NA                           18/14                                NA                            16/12                                NA                                                   20/16                                     17/5                                                  NA                                      OS DFS                 7
                                     5/53              12/14                     12/18                                                   8/14                                     11/25                                                                                                                                                                                                                                                                                                                                                    
  Harimoto et al[@b18-ott-11-1293]   2004    Japan     HCC     60                Novocastra Laboratories, Ltd   1:200                    26/34                                    19/27                        NA                                   10/20                         NA                                   6/6                                                  9/14                                      8/13                                                  NA                                      OS DFS                 8
                                     NA      7/7               16/14                                            20/28                    17/20                                    18/21                                                                                                                                                                                                                                                                                                                                                    
  Zhang et al[@b19-ott-11-1293]      2016    China     HCC     167               Cell sigaling Technology       1:1,000                  81/86                                    NA                           NA                                   NA                            NA                                   NA                                                   NA                                        NA                                                    NA                                      Os DFs                 9
  Hung et al[@b25-ott-11-1293]       2017    China     HCC     80                Abcam                          1:750                    NA                                       53/8                         NA                                   NA                            NA                                   NA                                                   NA                                        19/0                                                  39/8                                    OS                     8
                                             15/4                                                                                                                                 49/12                        29/4                                                                                                                                                                                                                                                                                                                        

**Note:** + means over-expressed and - means lower-expressed.

**Abbreviations:** AFP, α-fetoprotein; DFS, disease-free survival; HBsAg, hepatitis B virus surface antigen; HCC, hepatocellular carcinoma; OS, overall survival; UICC, Union for International Cancer Control; NA, not applicable.

###### 

HSP27 clinicopathological features for HCC

  Heterogeneity                                                             
  ------------------- --- ----- -------------------- ------- ------ ------- --------
  Expression          5   237   7.00 (2.35--20.79)   0.002   76.6   0.000   Random
  Gender              6   478   1.13 (0.72--1.77)    0.142   39.5   0.606   Fixed
  AFP                 3   167   3.86 (1.11--13.39)   0.113   54.2   0.034   Random
  HBsAg               6   492   1.72 (0.65--4.52)    0.001   74.8   0.275   Random
  Tumor size          6   304   1.19 (0.74--1.92)    0.535   0.0    0.479   Fixed
  Metastasis          6   471   1.96 (0.91--4.24)    0.013   65.2   0.086   Random
  Vascular invasion   7   530   1.71 (0.93--3.15)    0.037   55.2   0.083   Random
  Differentiation     9   642   3.81 (1.79--8.08)    0.012   59.0   0.000   Random
  TNM stage           5   444   0.68 (0.33--1.38)    0.068   54.2   0.282   Random

**Abbreviations:** AFP, α-fetoprotein; Fixed, fixed-effects model; HCC, hepatocellular carcinoma; OR, odds ratio; Random, random-effects model.
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